E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00388726|
Recruitment Status : Completed
First Posted : October 17, 2006
Results First Posted : January 30, 2012
Last Update Posted : January 7, 2020
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: E7389 Drug: Physician's Choice||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||762 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane|
|Actual Study Start Date :||November 2006|
|Actual Primary Completion Date :||May 2009|
|Actual Study Completion Date :||June 2013|
1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
|Active Comparator: 2||
Drug: Physician's Choice
Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
- Overall Survival [ Time Frame: From date of randomization until death from any cause ]Defined as the time from the date of randomization until the date of death from any cause.
- Progression-Free Survival. [ Time Frame: Until disease progression or death. ]Measured using Response Evaluation Criteria in Solid Tumors (RECIST) and defined as the time from the date of randomization until progressive disease or death from any cause in the absence of of progressive disease.
- Best Overall Response [ Time Frame: Until Day 30 or every 3 months during Follow-up period for patients who complete study without PD. ]Measured by RECIST criteria and defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
- Duration of Response. [ Time Frame: From first documented CR or PR until disease progression or death. ]As measured by RECIST criteria and defined as the time from the first documented CR or PR until disease progression or death from any cause.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: From start of study drug administration up to 30 days after the last dose of study drug (approximately up to 42 months) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388726